The University of Pittsburgh Cancer Institute (UPCI) is a multidisciplinary cancer research center, with programs in basic research, translational research and clinical investigations; cancer control and population sciences, early diagnosis and treatment, and behavioral medicine research. In addition to its central role in all cancer research at the University of Pittsburgh, it has full responsibility for cancer education and a recently significantly expanded network of clinical care. The UPCI is comprised of faculty members from the University of Pittsburgh, with some members also from the nearby Carnegie Mellon University, and it utilizes the clinical facilities of the University of Pittsburgh Medical Center (UPMC) and UPMC Cancer Centers. The UPCI has established programs in: molecular and cellular oncology, molecular therapeutics and drug discovery, immunology, molecular virology, lung and thoracic malignancies, prostate and urologic cancers, head and neck cancer, biological therapeutics, brain tumors; cancer epidemiology, prevention and control; and behavioral medicine and oncology. To assist its research efforts, the UPCI maintains shared facilities including: Biostatistics, Clinical Research Services, Immunologic Monitoring Laboratory, Cellular Products Laboratory, Flow Cytometry, Peptide Synthesis, Animal, Glassware, Oligonucleotide, Cell and Tissue Imaging, PET, MRI, Basic Genomics and Proteomics, Clinical Proteomics, Vector, Transgenic and Chimeric Mouse, Tissue and Research Pathology Services (TARPS), Clinical Pharmacology and Analytical, Cancer Informatics Services, Investigational Drug Service, and Micro-array and Analysis Shared Services(MASS). This application requests continued cancer center support grant (CCSG) funding for the University of Pittsburgh Cancer Institute's program for years 17-22.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-20
Application #
7279259
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-10
Project End
2009-07-31
Budget Start
2007-09-06
Budget End
2008-07-31
Support Year
20
Fiscal Year
2007
Total Cost
$5,204,424
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Du, Tian; Sikora, Matthew J; Levine, Kevin M et al. (2018) Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 20:106
Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Song, Xinxin; Zhu, Shan; Xie, Yangchun et al. (2018) JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology 154:1480-1493
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:

Showing the most recent 10 out of 1187 publications